263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET).

Authors :: Rodriguez Hernandez, A.
Martinez Saez, O.
Brasó-Maristany, F.
Pastor, B.
Potrony, M.
Moreno, L.
Grau, E.
Puig-Butille, J.A.
Sánchez, A.
Schettini, F.
Conte, B.
Chic, N.
Vidal Losada, M.J.
Munoz, M.
Balaguer, F.
Prat, A.
Adamo, B.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS657-S658. 2p.
Publication Year :: 2022

Subjects :: *CYCLIN-dependent kinase inhibitors
*HORMONE therapy
*TREATMENT effectiveness
*GERM cells
*GENES

Full Text Access

Tools